Pathogenesis and management of refractory malignant ascites;Physiopathologie et prise en charge des ascites malignes réfractaires

Bulletin du Cancer

Volumn 98, Issue 6, 2011, Pages 679-687

  Saâda, Esma ^a   Follana, Philippe ^a   Peyrade, Fréderic ^a   Mari, Véronique ^a   François, Éric ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Catumaxomab; EpCAM; Immunotherapy; Malignant ascites; Paracentesis; VEGF

Indexed keywords

ABDOMINAL BULGE; ANOREXIA; ASCITES; BREAST ADENOCARCINOMA; CARCINOMATOUS PERITONITIS; COLON ADENOCARCINOMA; DISEASE ASSOCIATION; DYSPNEA; HEART FAILURE; HUMAN; MALIGNANT ASCITES; NAUSEA; OVARY ADENOCARCINOMA; PALLIATIVE THERAPY; PANCREAS ADENOCARCINOMA; PERIPHERAL EDEMA; PERITONEAL CAVITY; PORTAL HYPERTENSION; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; STOMACH ADENOCARCINOMA; VOMITING;

EID: 79959361649     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1373     Document Type: Review

References (90)

1. Chung M, Kozuch P. Treatment of malignant ascites. Curr Treat Options Oncol 2008 ; 9 : 215-33.
2. Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988 ; 8 : 1104-9.
3. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007 ; 18 : 945-9. (Pubitemid 47054094)
4. Holm-Nielsen P. Pathogenesis of ascites in peritoneal carcinomatosis. Acta Pathol Microbiol Scand 1953 ; 33 : 10-21.
5. Baron MA. Structure of the intestinal peritoneum in man. Am J Anat 1941 ; 69 : 439.
6. Renkin EM. Some consequences of capillary permeability to macromolecules: Starling's hypothesis reconsidered. Am J Physiol 1986 ; 250 : H706-10.
7. Starling EH. On the absorption of fluids from the connective tissue spaces. J Physiol 1896 ; 19 : 312-26.
8. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983 ; 219 : 983-5.
9. Garrison RN, Kaelin LD, Galloway RH, Heuser LS. Malignant ascites. Clinical and experimental observations. Ann Surg 1986 ; 203 : 644-51.
10. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999 ; 6 : 373-8. (Pubitemid 29260800)
11. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999 ; 85 : 178-87. (Pubitemid 29031373)
12. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995 ; 146 : 1029-39.
13. Runyon BA. Care of patients with ascites. N Engl J Med 1994 ; 330 : 337-42. (Pubitemid 24984679)
14. Gotlieb WH, Feldman B, Feldman-Moran O, et al. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynecol Oncol 1998 ; 71 : 381-5. (Pubitemid 29022323)
15. Ross GJ, Kessler HB, Clair MR, Gatenby RA, Hartz WH, Ross LV. Sonographically guided paracentesis for palliation of symptomatic malignant ascites. AJR Am J Roentgenol 1989 ; 153 : 1309-11. (Pubitemid 20006559)
16. McNamara P. Paracentesis - an effective method of symptom control in the palliative care setting? Palliat Med 2000 ; 14 : 62-4.
17. Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 1996 ; 22 : 237-9. (Pubitemid 26229671)
18. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006 ; 42 : 589-97. (Pubitemid 43343680)
19. Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manage 1998 ; 16 : 96-101. (Pubitemid 28400159)
20. Rosenberg S, Courtney A, Nemcek Jr. AA, Omary RA. Comparison of percutaneous management techniques for recurrent malignant ascites. J Vasc Interv Radiol 2004 ; 15 : 1129-31. (Pubitemid 39346694)
21. Fischer DS. Abdominal paracentesis for malignant ascites. Arch Intern Med 1979 ; 139 : 235.
22. Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg 2004 ; 198 : 999-1011. (Pubitemid 38759851)
23. Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 2003 ; 15 : 59-72. (Pubitemid 36348121)
24. Richard 3rd. HM, Coldwell DM, Boyd-Kranis RL, Murthy R, Van Echo DA. Pleurx tunneled catheter in the management of malignant ascites. J Vasc Interv Radiol 2001 ; 12 : 373-5. (Pubitemid 32217038)
25. Leveen HH, Christoudias G, Ip M, Luft R, Falk G, Grosberg S. Peritoneo-venous shunting for ascites. Ann Surg 1974 ; 180 : 580-91.
26. Seike M, Maetani I, Sakai Y. Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis. J Gastroenterol Hepatol 2007 ; 22 : 2161-6. (Pubitemid 350145620)
27. Schumacher DL, Saclarides TJ, Staren ED. Peritoneovenous shunts for palliation of the patient with malignant ascites. Ann Surg Oncol 1994 ; 1 : 378-81.
28. Bieligk SC, Calvo BF, Coit DG. Peritoneovenous shunting for nongynecologic malignant ascites. Cancer 2001 ; 91 : 1247-55. (Pubitemid 32267034)
29. Zanon C, Grosso M, Apra F, et al. Palliative treatment of malignant refractory ascites by positioning of Denver peritoneovenous shunt. Tumori 2002 ; 88 : 123-7. (Pubitemid 34602183)
30. Clara R, Righi D, Bortolini M, Cornaglia S, Ruffino MA, Zanon C. Role of different techniques for the placement of Denver peritoneovenous shunt (PVS) in malignant ascites. Surg Laparosc Endosc Percutan Tech 2004 ; 14 : 222-5. (Pubitemid 39100954)
31. Tomiyama K, Takahashi M, Fujii T, et al. Improved quality of life for malignant ascites patients by Denver peritoneovenous shunts. Anticancer Res 2006 ; 26 : 2393-5. (Pubitemid 43980207)
32. Lund RH, Moritz MW. Complications of Denver peritoneovenous shunting. Arch Surg 1982 ; 117 : 924-8. (Pubitemid 12080910)
33. Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984 ; 44 : 3584-92. (Pubitemid 14098615)
34. Gough IR, Balderson GA. Malignant ascites. A comparison of peritoneovenous shunting and nonoperative management. Cancer 1993 ; 71 : 2377-82.
35. Souter RG, Tarin D, Kettlewell MG. Peritoneovenous shunts in the management of malignant ascites. Br J Surg 1983 ; 70 : 478-81. (Pubitemid 13030845)
36. Pockros PJ, Esrason KT, Nguyen C, Duque J, Woods S. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 1992 ; 103 : 1302-6.
37. Mackey JR, Venner PM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol 1996 ; 6 : 474-80.
38. Schilsky RL, Choi KE, Grayhack J, Grimmer D, Guarnieri C, Fullem L. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol 1990 ; 8 : 2054-61.
39. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992 ; 118 : 547-50.
40. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000 ; 66 : 561-8. (Pubitemid 30396247)
41. Yan TD, Stuart OA, Yoo D, Sugarbaker PH. Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. J Transl Med 2006 ; 4 : 17.
42. Garofalo A, Valle M, Garcia J, Sugarbaker PH. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol 2006 ; 32 : 682-5. (Pubitemid 44064001)
43. Los G, Smals OA, van Vugt MJ, et al. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 1992 ; 52 : 1252-8.
44. Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999 ; 6 : 582-90. (Pubitemid 29428799)
45. Francois Y, Grandclement E, Sayag-Beaujard AC, et al. Intraperitoneal chemo-hyperthermia with mitomycin c in cancer of the stomach with peritoneal carcinosis. J Chir (Paris) 1997 ; 134 : 237-42. (Pubitemid 28042064)
46. Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor bb94 in patients with malignant ascites. Clin Cancer Res 1998 ; 4 : 1899-902. (Pubitemid 28369173)
47. Parsons SL, Watson SA, Steele RJ. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997 ; 23 : 526-31. (Pubitemid 28059777)
48. Stuart GC, Nation JG, Snider DD, Thunberg P. Intraperitoneal interferon in the management of malignant ascites. Cancer 1993 ; 71 : 2027-30. (Pubitemid 23068552)
49. Lissoni P, Barni S, Tancini G, et al. Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon alpha, beta and interleukin-2. Support Care Cancer 1995 ; 3 : 78-80.
50. Rath U, Kaufmann M, Schmid H, et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer 1991 ; 27 : 121-5.
51. Katano M, Morisaki T. The past, the present and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res 1998 ; 18 : 3917-25. (Pubitemid 28561081)
52. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998 ; 153 : 1249-56. (Pubitemid 28465848)
53. Ninomiya S, Inomata M, Tajima M, et al. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of mnk-45p human gastric cancer in mice. J Surg Res 2009 ; 154 : 196-202.
54. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 2008 ; 111 : 530-2.
55. Shami EK. Pilot trial of intraperitoneal bevacizumab as a palliative treatment in refractory malignant ascite. ASCO Gastrointestinal Cancers Symposium.
56. Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006 ; 102 : 425-8. (Pubitemid 44353660)
57. Bezwoda WR, Seymour L, Dansey R. Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer. Cancer 1989 ; 64 : 1029-33. (Pubitemid 19208853)
58. Sartori S, Nielsen I, Tassinari D, Trevisani L, Abbasciano V, Malacarne P. Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology 2001 ; 61 : 192-6. (Pubitemid 34701533)
59. Gebbia V, Russo A, Gebbia N, et al. Intracavitary beta-interferon for the management of pleural and/or abdominal effusions in patients with advanced cancer refractory to chemotherapy. In Vivo 1991 ; 5 : 579-81.
60. Hirte HW, Miller D, Tonkin K, et al. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. Gynecol Oncol 1997 ; 64 : 80-7. (Pubitemid 27026961)
61. Yamaguchi Y, Satoh Y, Miyahara E, et al. Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res 1995 ; 15 : 2201-6. (Pubitemid 26031301)
62. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO GJ. Ep-CAM. A human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994 ; 125 : 437-46. (Pubitemid 24135956)
63. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1a antigen (Ep-CAM). J Mol Med 1999 ; 77 : 699-712.
64. Went PT, Lugli A, Meier S, et al. Frequent EpCAM protein expression in human carcinomas. Hum Pathol 2004 ; 35 : 122-8. (Pubitemid 38133932)
65. Amann M, Brischwein K, Lutterbuese P, et al. Therapeutic window of MUS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res 2008 ; 68 : 143-51. (Pubitemid 351380115)
66. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004 ; 23 : 5748-58. (Pubitemid 39093020)
67. Armstrong A, Eck SL. EpCAM. A new therapeutic target for an old cancer antigen. Cancer Biol Ther 2003 ; 2 : 320-6.
68. Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC. EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer 2007 ; 96 : 1013-9. (Pubitemid 46608303)
69. Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004 ; 64 : 5818-24. (Pubitemid 39095582)
70. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998 ; 16 : 1788-94.
71. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' colorectal carcinoma. German cancer aid 17-1a study group. Lancet 1994 ; 343 : 1177-83. (Pubitemid 24147551)
72. Hartung G, Hofheinz RD, Dencausse Y, et al. Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie 2005 ; 28 : 347-50. (Pubitemid 40827490)
73. Colacchio TA, Niedzwiecki D, Compton C, et al. Phase III trial of adjuvant immunotherapy with moab 17-1 following resection of stage II adenocarcinoma of the colon (calgb 9581). J Clin Oncol 2004 ; 22, abstract 3522.
74. Punt CJ, Nagy A, Douillard JY, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002 ; 360 : 671-7. (Pubitemid 35232335)
75. Fields AL, Keller A, Schwartzberg L, et al. Adjuvant therapy with the monoclonal antibody edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 2009 ; 27 : 1941-7.
76. Schmoll HJ, Arnold D. When wishful thinking leads to a mistyeyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab. J Clin Oncol 2009 ; 27 : 1926-9.
77. Zeidler R, Mysliwietz J, Csanady M, et al. The FC-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000 ; 83 : 261-6. (Pubitemid 30411727)
78. Ruf P, Gires O, Jager M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007 ; 97 : 315-21. (Pubitemid 47196752)
79. Schmitt M, Schmitt A, Reinhardt P, et al. Opsonization with a trifunctional bispecific (alphacd3xalphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 2004 ; 25 : 841-8.
80. Zeidler R, Reisbach G, Wollenberg B, et al. Simultaneous activation of t cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999 ; 163 : 1246-52. (Pubitemid 29352740)
81. Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAMxalpha CD3). J Histochem Cytochem 2001 ; 49 : 911-7. (Pubitemid 32565984)
82. Heiss MM, Strohlein MA, Jager M, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005 ; 117 : 435-43. (Pubitemid 41429567)
83. Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-cd3 antibody: a phase I/II study. Clin Cancer Res 2007 ; 13 : 3899-905. (Pubitemid 47037597)
84. Stroehlein MA, LF MA, Ruettinger D, Peschel C, Heiss MM. Treatment of peritoneal carcinomatosis due to gi-tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpCAM x anti-cd3): results of a phase I/II trial. J Clin Oncol 2005 ; 23, abstract 2529.
85. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010 ; 127 : 2209-21.
86. Sebastian M, Passlick B, Friccius-Quecke H, et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-cd3): a phase I study. Cancer Immunol Immunother 2007 ; 56 : 1637-44. (Pubitemid 47094393)
87. Riechelmann H, Wiesneth M, Schauwecker P, et al. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother 2007 ; 56 : 1397-406. (Pubitemid 47024704)
88. Prang N, Preithner S, Brischwein K, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody mt201 against breast cancer cell lines. Br J Cancer 2005 ; 92 : 342-9. (Pubitemid 40343151)
89. Ko YJ, Bubley GJ, Weber R, et al. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine emd 273066 (huks-il2): results of a phase I trial in patients with prostate cancer. J Immunother 2004 ; 27 : 232-9. (Pubitemid 39118088)
90. MacDonald GC, Glover N. Effective tumor targeting: strategies for the delivery of armed antibodies. Curr Opin Drug Discov Devel 2005 ; 8 : 177-83. (Pubitemid 40348970)